NASC (Nascent Pharma Holdings) Piotroski F-Score: 0 (As of Jun. 26, 2026)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.01
View Full Analysis

What is Nascent Pharma Holdings Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nascent Pharma Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Nascent Pharma Holdings's Piotroski F-Score or its related term are showing as below:

Nascent Pharma Holdings  (OTCPK:NASC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Nascent Pharma Holdings Piotroski F-Score Related Terms


Nascent Pharma Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Piotroski F-Score Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 2.00 3.00 3.00

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 3.00 4.00
NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -1.806 + -6.161 + -2.029 + -3.263 = $-13.26 Mil.
Cash Flow from Operations was 0.151 + 0.217 + -0.131 + 0.009 = $0.25 Mil.
Revenue was 0.377 + 0.369 + 0.272 + 0.015 = $1.03 Mil.
Gross Profit was 1.274 + -0.824 + -0.393 + -0.401 = $-0.34 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(13.075 + 10.126 + 5.322 + 4.92 + 1.856) / 5 = $7.0598 Mil.
Total Assets at the begining of this year (Sep23) was $13.08 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $1.59 Mil.
Total Current Liabilities was $11.64 Mil.
Net Income was -2.899 + -1.739 + -2.027 + -4.165 = $-10.83 Mil.

Revenue was 0.666 + 0.939 + 0.421 + 0.419 = $2.45 Mil.
Gross Profit was -0.155 + 0.415 + -0.514 + -0.817 = $-1.07 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(16.719 + 15.56 + 15.577 + 14.581 + 13.075) / 5 = $15.1024 Mil.
Total Assets at the begining of last year (Sep22) was $16.72 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $7.63 Mil.
Total Current Liabilities was $12.86 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nascent Pharma Holdings's current Net Income (TTM) was -13.26. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nascent Pharma Holdings's current Cash Flow from Operations (TTM) was 0.25. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-13.259/13.075
=-1.01407266

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-10.83/16.719
=-0.64776601

Nascent Pharma Holdings's return on assets of this year was -1.01407266. Nascent Pharma Holdings's return on assets of last year was -0.64776601. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Nascent Pharma Holdings's current Net Income (TTM) was -13.26. Nascent Pharma Holdings's current Cash Flow from Operations (TTM) was 0.25. ==> 0.25 > -13.26 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0/7.0598
=0

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0/15.1024
=0

Nascent Pharma Holdings's gearing of this year was 0. Nascent Pharma Holdings's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=1.594/11.644
=0.13689454

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=7.633/12.856
=0.59373055

Nascent Pharma Holdings's current ratio of this year was 0.13689454. Nascent Pharma Holdings's current ratio of last year was 0.59373055. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Nascent Pharma Holdings's number of shares in issue this year was 65.436. Nascent Pharma Holdings's number of shares in issue last year was 11.59. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.344/1.033
=-0.33301065

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-1.071/2.445
=-0.43803681

Nascent Pharma Holdings's gross margin of this year was -0.33301065. Nascent Pharma Holdings's gross margin of last year was -0.43803681. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=1.033/13.075
=0.07900574

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=2.445/16.719
=0.1462408

Nascent Pharma Holdings's asset turnover of this year was 0.07900574. Nascent Pharma Holdings's asset turnover of last year was 0.1462408. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nascent Pharma Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.


Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price